Atopic keratoconjunctivitis

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
1 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Dompe' Farmaceutici S.p.A. Commercial
    (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-ETHYL-34-[(E,2R)-HEX-4-EN-2-YL]-4,7,10,12,15,19,25,28-OCTAMETHYL-33-(METHYLAMINO)-6,9,18,24-TETRAKIS(2-METHYLPROPYL)-3,21-DI(PROPAN-2-YL)-1-OXA-4,7,10,13,16,19,22,25,28,31-DECAZACYCLOTETRATRIACONTANE-2,5,8,11,14,17,20,23,26,29,32-UNDECONE HYDROCHLORIDE
    2025-522291-83-00 2 countries 2025 n=104
    Recruiting

Phase II

1 trial
  • Dompe' Farmaceutici S.p.A. Commercial
    (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-ETHYL-34-[(E,2R)-HEX-4-EN-2-YL]-4,7,10,12,15,19,25,28-OCTAMETHYL-33-(METHYLAMINO)-6,9,18,24-TETRAKIS(2-METHYLPROPYL)-3,21-DI(PROPAN-2-YL)-1-OXA-4,7,10,13,16,19,22,25,28,31-DECAZACYCLOTETRATRIACONTANE-2,5,8,11,14,17,20,23,26,29,32-UNDECONE HYDROCHLORIDE
    2023-508907-19-00 1 country 2024 n=69
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Dompe' Farmaceutici S.p.A. Commercial 2 Phase II, Phase III 1
New trials by year
2024
1
2025
1
← All indication landscapes